H.C. Wainwright analyst Vernon Bernardino raised the firm’s price target on Novavax to $101 from $50 and reiterates a Buy rating on the shares. The stock closed Friday down $6.15 to $77.39. After speaking with management, the analyst increased his positive view on the prospects for Novavax to realize a “sustained commercial opportunity.” The company’s capability to be a “robust competitor” against larger vaccine makers suggests it could realize greater than $400M in annual sales of NVX-CoV2373, Bernardino tells investors in a research note. The analyst continues to view Novavax as a top pick.